Juergen Kurz – General Manager, HEUFT China
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
Founded in 1988, the China Pharmaceutical Innovation and Research Development Association (PhIRDA) is registered as a non-profit organization by the Ministry of Civil Affairs of China at the first national level. PhIRDA will exert great effort on “academia-industry collaboration”, which centres on the principle of “innovation, industrialization, internationalization” and persists in innovation to achieve unmet clinical requirements.
Currently, PhIRDA has 142 members, which mainly consist of five major categories: First, start-up and R&D enterprises focusing on innovation of pharmaceutical products; Second, domestic first-class universities, colleges and research institutions conducting pharmaceutical research and development; Third clinical institutions featuring high skills in applicable research on new drugs, especially those that undertake “major new drug innovation” technological platform for good clinical practice; Fourth, investment institutions committing to pharmaceutical innovation; Fifth, national pharmaceutical enterprises excelling at innovation; Moreover, PhIRDA has established a Drug R&D Specialty Committee, Clinical Research Specialty Committee, Medicinal Policy Specialty Committee and Pharmaceutical Innovation Investment Specialty Committee, in order to promote innovation as the goal of organizational structure.
PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) to continuously broaden channels of international collaboration.
Contact
Address: Room 601, CTYS Plaza, No. 5 Dongzhimen South Street, Dongcheng District, Beijing, P.R. CHINA
Tel: +86 10-58156353
Email: luxt@phirda.com, ruanxx@phirda.com
Juergen Kurz takes us through HEUFT’s unique technology that is revolutionizing the quality of packaging in the pharmaceutical industry in a country, China, where quality compliance is now an issue. …
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry. The amended law seeks to address prominent problems in the pharmaceutical…
China’s new Amended Drug Administration Law is being enacted to strengthen and streamline its regulation of the pharmaceutical industry as well as address prominent problems such as counterfeit drugs, substandard…
Tao Chen, head of business development of Absea and CEO of the new spin-out Agsea, is entering the world of immunodiagnostics with a comprehensive panel of IHC antibodies in the…
China’s booming pharmaceutical industry has been rapidly expanding to become the second largest pharmaceutical market globally. The following are the top ten Chinese pharma companies from 2018, with revenues reaching over…
Dr CJ Wang, CEO of Frontier Biotech, shares his exciting ten-year journey with Frontier and their distinctive focus on HIV drug development, with their flagship compound, Aikening®, launched in China…
Dr Laura Benjamin, CEO of Oncologie, shares the rationale behind their exceptional decision to simultaneously establish offices in both the US and China; their unique biomarker approach focusing on the…
Shirley Xu, president of Baxter Greater China, reflects on her extraordinary 26-year (and counting) career with Baxter China, including her perspectives on the success factors behind Baxter’s growth in the…
John Moller, CEO; and Yooni Kim, executive director of Asia operations, for Novotech, share the competitive positioning of Novotech as a full-service CRO for biotech companies interested in the Asia-Pacific…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Kevin Pan, CEO of Asieris, shares the origins behind the company’s distinctive name and how it reflects their ambition to bridge scientific discoveries and innovative medicines; their focus on genitourinary…
Dr Irwin Wang, CEO of Reistone Biopharma, shares her motivations behind the establishment of the company, their extremely productive collaboration with Jiangsu Hengrui (China’s largest pharma company by market capitalization),…
See our Cookie Privacy Policy Here
